沃森生物9月24日获融资买入3158.41万元，融资余额19.20亿元

Core Insights - Watson Bio's stock increased by 0.51% on September 24, with a trading volume of 229 million yuan [1] - The company experienced a net financing outflow of 5.95 million yuan on the same day, indicating a decrease in investor confidence [1] Financing Summary - On September 24, Watson Bio had a financing buy-in of 31.58 million yuan, while the financing repayment was 37.53 million yuan, resulting in a net financing buy-in of -5.95 million yuan [1] - The total financing and securities balance as of September 24 was 1.928 billion yuan, with the financing balance at 1.920 billion yuan, accounting for 10.23% of the circulating market value [1] - The financing balance is currently below the 30th percentile level over the past year, indicating a low position [1] Securities Lending Summary - On September 24, Watson Bio repaid 6,600 shares in securities lending and sold 6,100 shares, with a selling amount of 71,600 yuan based on the closing price [1] - The remaining securities lending volume was 722,000 shares, with a securities lending balance of 8.4685 million yuan, which is above the 90th percentile level over the past year, indicating a high position [1] Company Overview - Yunnan Watson Bio Technology Co., Ltd. was established on January 16, 2001, and listed on November 12, 2010 [1] - The company's main business involves the research, production, and sales of vaccine products, with 94.82% of its revenue coming from self-developed vaccines [1] Financial Performance - As of June 30, 2025, Watson Bio reported a revenue of 1.154 billion yuan, a year-on-year decrease of 19.47%, and a net profit attributable to shareholders of 43.16 million yuan, down 74.69% year-on-year [2] - The company has distributed a total of 403 million yuan in dividends since its A-share listing, with 47.98 million yuan distributed in the last three years [2] Shareholder Structure - As of June 30, 2025, Watson Bio had 117,300 shareholders, an increase of 3.73% from the previous period, with an average of 13,268 circulating shares per person, a decrease of 3.88% [2] - The largest circulating shareholder is E Fund's ChiNext ETF, holding 40.27 million shares, a decrease of 1.0618 million shares from the previous period [2]